# Ginkgolide **Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/ginkgolide **Data Source:** Hermetica Superfoods Ingredient Encyclopedia **Updated:** 2026-03-29 **Evidence Score:** 2 / 10 **Category:** Compound **Also Known As:** diterpene trilactones, Ginkgo biloba trilactones, GB trilactones, ginkgolide compounds, diterpene lactones from Ginkgo, Ginkgo trilactone derivatives ## Overview Ginkgolides are a class of diterpene lactones extracted primarily from Ginkgo biloba leaves and roots, with ginkgolide B being the most pharmacologically studied compound. They act as potent antagonists of platelet-activating factor (PAF) receptors, which plays a role in platelet aggregation, [inflammation](/ingredients/condition/inflammation), and neurological signaling. ## Health Benefits • No specific health benefits are documented due to the lack of human clinical trials or RCTs. • The research dossier does not provide data to support health claims. • Extraction and isolation focus in studies preclude direct health implications. • Typical research emphasizes chemical characterization over clinical application. • There is no evidence-based health benefit due to an absence of clinical data. ## Mechanism of Action Ginkgolides, particularly ginkgolide B (BN 52021), function as selective competitive antagonists of the platelet-activating factor (PAF) receptor, blocking PAF-induced platelet aggregation and [inflammatory](/ingredients/condition/inflammation) cascade activation. Ginkgolide B also inhibits glycine receptor chloride channels in the central nervous system, modulating inhibitory neurotransmission. Additionally, some ginkgolides interfere with [mitochondrial](/ingredients/condition/energy) permeability transition pore (mPTP) opening, potentially reducing apoptotic signaling under [oxidative stress](/ingredients/condition/antioxidant) conditions. ## Clinical Summary Human clinical trials specifically isolating ginkgolides as standalone compounds are largely absent from the published literature, making it difficult to draw direct therapeutic conclusions. Most human research has been conducted on standardized Ginkgo biloba extracts (e.g., EGb 761), which contain 6% ginkgolides and bilobalide combined, complicating attribution of effects to ginkgolides alone. In vitro and animal studies have demonstrated ginkgolide B's PAF antagonism at micromolar concentrations, and small pilot studies in humans have noted reduced PAF-induced platelet aggregation ex vivo. Overall, the evidence base for isolated ginkgolide supplementation in humans remains preclinical, and robust RCTs with quantified outcomes are lacking. ## Nutritional Profile Ginkgolide is a bioactive terpenoid compound (specifically a diterpene trilactone) isolated from Ginkgo biloba, not a nutritional ingredient in the conventional sense and thus lacks macronutrient or micronutrient profile. It is not a source of protein, carbohydrates, fats, vitamins, or dietary fiber. Ginkgolides are classified into subtypes: Ginkgolide A, B, C, J, and M, with Ginkgolide B being the most pharmacologically studied. They are present in Ginkgo biloba leaf extracts at approximately 0.06–0.23% of dry leaf weight, and in standardized EGb 761 extract (the most studied commercial extract) ginkgolides constitute roughly 2.8–3.4% of the total extract by weight combined with bilobalide. Ginkgolide B is typically present at concentrations of 0.4–1.0 mg per standardized 120 mg EGb 761 dose. These compounds are lipophilic in nature, contributing to moderate oral bioavailability estimated at approximately 80% for Ginkgolide A and 60–70% for Ginkgolide B based on pharmacokinetic studies in human volunteers. They are not sources of calories or essential nutrients. Their biochemical significance lies solely in their role as platelet-activating factor (PAF) receptor antagonists, a pharmacological rather than nutritional property. No RDI or dietary reference intake exists for ginkgolides. ## Dosage & Preparation There are no clinically studied dosage ranges or forms reported in the research. Consult a healthcare provider before starting any new supplement. ## Safety & Drug Interactions Ginkgolides, via their PAF-antagonist activity, may potentiate the effects of antiplatelet drugs such as aspirin, clopidogrel, and warfarin, increasing bleeding risk when combined. Reported adverse effects from Ginkgo biloba extracts containing ginkgolides include headache, gastrointestinal upset, and allergic skin reactions, though causation by ginkgolides specifically has not been isolated. Ginkgolide B's inhibition of glycine receptors raises theoretical concerns for individuals with seizure disorders, as glycinergic inhibition plays a role in seizure threshold. Pregnant and breastfeeding women are advised to avoid ginkgolide-containing supplements due to insufficient safety data and theoretical platelet-inhibiting risks. ## Scientific Research The dossier does not reference any human clinical trials, RCTs, or meta-analyses for ginkgolides, reflecting a focus on extraction and chemical characterization methods. ## Historical & Cultural Context The research dossier lacks information on the traditional or historical medicinal uses of ginkgolides. The focus remains on extraction and chemical properties without addressing cultural contexts. ## Synergistic Combinations Ginkgo biloba leaf extract, bacopa monnieri, phosphatidylserine ## Frequently Asked Questions ### What is ginkgolide B and what does it do? Ginkgolide B (also called BN 52021) is the most studied diterpene lactone isolated from Ginkgo biloba and acts as a selective antagonist of the platelet-activating factor (PAF) receptor. By blocking PAF binding, it inhibits PAF-induced platelet aggregation and suppresses downstream inflammatory mediator release, including thromboxane A2 and interleukins. ### Are there human clinical trials on ginkgolide supplements? Isolated ginkgolide supplements have not been the subject of large-scale human RCTs. Most available human data comes from standardized Ginkgo biloba extract studies such as EGb 761, which contains approximately 6% combined ginkgolides and bilobalide, making it impossible to attribute outcomes solely to ginkgolides. Dedicated Phase II or III clinical trials on purified ginkgolide compounds are currently lacking in the published literature. ### Can ginkgolides interact with blood thinners like warfarin? Yes, ginkgolides pose a clinically relevant interaction risk with anticoagulant and antiplatelet medications including warfarin, aspirin, and clopidogrel. Their PAF-receptor antagonism adds an independent antiplatelet mechanism that can synergize with these drugs, potentially increasing the risk of prolonged bleeding or hemorrhage. Patients on blood-thinning therapy should consult a physician before using any Ginkgo biloba or ginkgolide-containing product. ### What is the difference between ginkgolides and bilobalide? Ginkgolides (A, B, C, J, and M) and bilobalide are both terpenoid compounds found in Ginkgo biloba, but they differ structurally and mechanistically. Ginkgolides are diterpene lactones primarily recognized for PAF receptor antagonism, while bilobalide is a sesquiterpene trilactone studied mainly for neuroprotective and GABA-A receptor modulating properties. Standard Ginkgo extracts like EGb 761 contain roughly 3.1% ginkgolides and 2.9% bilobalide, with each contributing distinct pharmacological actions. ### What foods or plants naturally contain ginkgolides? Ginkgolides are found almost exclusively in Ginkgo biloba (maidenhair tree), one of the oldest living tree species on Earth. They are concentrated primarily in the leaves, roots, and bark, with ginkgolide content varying by plant age, extraction method, and plant part used. No other known dietary food sources contain pharmacologically significant levels of ginkgolides, making Ginkgo biloba extract the sole practical source for supplementation. ### What is the bioavailability of ginkgolides and how are they absorbed? Ginkgolides are lipophilic compounds extracted primarily from Ginkgo biloba leaves, and their absorption in the human body remains poorly characterized due to limited clinical research. Most available data focuses on chemical extraction and isolation methods rather than intestinal bioavailability or pharmacokinetic profiles in humans. The lipophilic nature of ginkgolides suggests they may require dietary fat for optimal absorption, but this has not been rigorously studied in clinical settings. ### Is ginkgolide supplementation safe for elderly individuals or those with bleeding disorders? While ginkgolides are generally considered safe in traditional use, specific safety data for elderly populations or individuals with bleeding disorders is limited due to the absence of human clinical trials. Given that some Ginkgo biloba constituents may have antiplatelet effects, elderly individuals or those at risk of bleeding should consult a healthcare provider before supplementation. No formal safety guidelines exist for ginkgolides as isolated compounds in vulnerable populations. ### How strong is the current scientific evidence supporting health claims about ginkgolides? The evidence base for ginkgolides is weak, as most published research focuses on chemical characterization and extraction methods rather than human clinical trials or randomized controlled studies demonstrating health benefits. No peer-reviewed RCTs in humans have established specific therapeutic claims for isolated ginkgolides. Until robust clinical evidence emerges, health claims about ginkgolides should be considered unsubstantiated from an evidence-based perspective. --- *Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com* *License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*